Respiratory failure is a serious clinical condition that nurses frequently encounter in critical care, emergency, and acute care settings. While supportive therapies such as oxygen and mechanical ventilation are often required, medications also play an important role in stabilizing patients and addressing the underlying causes. In this episode, we’ll review the general pharmacologic strategies used in the management of respiratory failure and highlight key considerations for nursing practice.
Aminoglycosides are antibiotics used to treat serious Gram-negative infections, but they also come with important safety concerns and unique pharmacokinetic properties that healthcare professionals must understand. In this episode, we’re going to break down the essential clinical pearls surrounding aminoglycosides and how pharmacists and clinicians can use them effectively while minimizing toxicity.
We’ll review the most common agents in this class, including Gentamicin, Tobramycin, and Amikacin, and discuss when these medications are typically used in clinical practice. From severe Gram-negative infections to synergy dosing in conditions like infective endocarditis, aminoglycosides still play a role in antimicrobial therapy.
Another key focus of this episode will be the pharmacology that makes these drugs unique. Aminoglycosides demonstrate concentration-dependent killing and a post-antibiotic effect, which is why strategies like extended-interval dosing and tools such as the Hartford Nomogram are commonly used to guide therapy.
We’ll also cover the major adverse effects, including nephrotoxicity and ototoxicity, and highlight practical monitoring strategies to help reduce these risks. By the end of this episode, you’ll have a clearer understanding of how aminoglycosides work, when they should be used, and the key dosing and monitoring principles that every clinician should know.
Chronic obstructive pulmonary disease (COPD) is a common chronic respiratory condition that nurses encounter frequently in both inpatient and outpatient settings. Effective pharmacologic management plays a major role in controlling symptoms, preventing exacerbations, and improving quality of life for patients living with COPD. In this episode, we’ll review the key medication classes used to manage COPD and highlight practical clinical considerations nurses should know when caring for these patients.
In this episode, we are going to take a closer look at Vancomycin, one of the most widely used antibiotics in the hospital setting and a medication that pharmacists frequently monitor. Vancomycin is a glycopeptide antibiotic primarily used to treat serious gram-positive infections, including those caused by Methicillin-resistant Staphylococcus aureus (MRSA). Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to the D-alanine–D-alanine portion of peptidoglycan precursors, which ultimately prevents the bacteria from forming a stable cell wall.
Clinically, vancomycin is commonly used for infections such as bacteremia, endocarditis, osteomyelitis, and severe skin and soft tissue infections when resistant gram-positive organisms are suspected. One of the most important aspects of vancomycin therapy is therapeutic drug monitoring, as maintaining appropriate exposure is critical for both efficacy and safety. Current practice often focuses on achieving target AUC-to-MIC ratios rather than relying solely on trough levels. Pharmacists also play an important role in adjusting doses based on renal function and monitoring for adverse effects.
Two key safety concerns with vancomycin are nephrotoxicity and vancomycin infusion-related reactions such as “red man syndrome,” which is characterized by flushing, rash, and hypotension if the medication is infused too rapidly. Throughout this episode, we will review the pharmacology, monitoring parameters, and clinical pearls that healthcare professionals should understand when managing patients receiving vancomycin therapy.
Asthma is a common chronic respiratory condition that nurses frequently encounter in both outpatient and inpatient settings. Effective medication management is essential for controlling symptoms, preventing exacerbations, and improving long-term respiratory health. In this episode, we’ll review the major medication classes used to manage asthma and highlight key nursing considerations when caring for patients with this condition.
In this episode, we are going to review antiarrhythmic drugs that clinicians may encounter in practice: Digoxin, Propafenone, Dofetilide, and a few others. While these drugs are commonly used in the management of atrial fibrillation and other rhythm disturbances, they each come with important pharmacology and safety considerations that pharmacists and healthcare providers need to recognize.
Digoxin is a cardiac glycoside that increases contractility while also slowing AV node conduction through enhanced vagal tone, making it useful for rate control in atrial fibrillation, particularly in patients with heart failure. However, it has a narrow therapeutic index, and toxicity can occur if renal function declines or electrolyte abnormalities develop.
Propafenone is a Class IC sodium channel blocker used primarily for rhythm control in atrial fibrillation. A key clinical pearl with this medication is that it should generally be avoided in patients with structural heart disease due to the risk of proarrhythmia.
Dofetilide and sotalol are both Class III antiarrhythmics that work by blocking potassium channels and prolonging cardiac repolarization. Because of their ability to prolong the QT interval, both agents carry a risk of torsades de pointes and require careful monitoring. Dofetilide initiation typically requires hospitalization to monitor the QT interval and adjust dosing based on renal function. Sotalol also requires attention to renal function and ECG monitoring, and it has additional beta-blocking effects that can contribute to bradycardia and fatigue.
Throughout this episode, we will break down the mechanisms, common clinical uses, and key safety pearls for these medications to help you better understand how they fit into arrhythmia management.
Antiarrhythmic medications are some of the most complex and high-risk drugs pharmacists encounter in clinical practice. In this episode, we break down the most important concepts pharmacists need to understand about antiarrhythmics, including the major drug classes and the clinical situations where these medications are commonly used.
A major focus of the discussion is medication safety. Many antiarrhythmics carry risks such as QT prolongation, proarrhythmia, and significant drug–drug interactions. Pharmacists play a critical role in identifying these risks, monitoring electrolytes and ECG changes, and recognizing situations where therapy adjustments are necessary. We also highlight why certain medications require inpatient initiation and careful monitoring.
The episode also covers practical clinical pearls, including the unique toxicity profile and interaction potential of amiodarone, how to think about rate control versus rhythm control strategies in atrial fibrillation, and the most common medication-related problems pharmacists should watch for. Whether practicing in ambulatory care, hospital, or long-term care settings, understanding antiarrhythmics can help pharmacists prevent serious complications and improve patient outcomes.
P2Y12 inhibitors are a cornerstone of antiplatelet therapy in cardiovascular disease. These agents block the P2Y12 receptor on platelets, preventing ADP-mediated activation and reducing platelet aggregation. By inhibiting this amplification pathway, they help prevent arterial thrombosis in conditions such as acute coronary syndrome, percutaneous coronary intervention, stroke, and peripheral artery disease. The most commonly used oral agents include clopidogrel, prasugrel, and ticagrelor, each with important pharmacokinetic and clinical differences that influence agent selection.
From a pharmacist’s perspective, choosing the right P2Y12 inhibitor requires balancing ischemic benefit with bleeding risk. Clopidogrel requires CYP2C19 activation and is subject to drug interactions and genetic variability. Prasugrel provides more potent inhibition but carries a higher bleeding risk and is contraindicated in patients with prior stroke or TIA. Ticagrelor offers reversible inhibition but comes with unique considerations such as dyspnea and drug interactions via CYP3A4. Understanding these nuances allows pharmacists to optimize dual antiplatelet therapy and improve patient outcomes.
In this episode, we explore several important non-statin cholesterol-lowering therapies, focusing on their mechanisms, clinical uses, and practical considerations for patient care.
We start with bile acid sequestrants, also known as resins, including cholestyramine, colestipol, and colesevelam. These medications lower LDL cholesterol by binding bile acids in the gut, prompting the liver to use more cholesterol to make new bile acids. They are effective for LDL reduction but may cause gastrointestinal side effects and have drug interaction considerations.
Next, we cover niacin (vitamin B3), which can lower LDL and triglycerides while raising HDL cholesterol. While niacin was historically widely used, its role has declined due to flushing, gastrointestinal symptoms, and potential liver toxicity.
Omega-3 fatty acids, including icosapent ethyl (EPA), primarily lower triglycerides and are used in patients with severe hypertriglyceridemia to reduce the risk of pancreatitis. Icosapent ethyl is a purified EPA formulation with evidence of cardiovascular benefit in select high-risk patients.
Finally, we discuss bempedoic acid, a newer oral agent that inhibits ATP-citrate lyase in the liver. Because it is activated only in the liver, bempedoic acid may be useful for patients with statin-associated muscle symptoms. Common adverse effects include elevated uric acid and mild increases in liver enzymes.
This episode highlights how these non-statin agents can be strategically used alone or in combination with other therapies to help patients reach their lipid goals and reduce cardiovascular risk.
Managing cholesterol is a key part of preventing cardiovascular disease, and nurses are on the front lines of patient care. In this episode, we explore the main cholesterol-lowering medications, including statins, ezetimibe, PCSK9 inhibitors, fibrates, and more. You’ll learn how each medication works, important side effects, lab monitoring, and nursing considerations for safe administration. We’ll also cover strategies for educating patients and supporting long-term adherence. By the end of this episode, you’ll have practical tools to confidently recognize, monitor, and teach about cholesterol medications in everyday nursing practice.
Your support helps me provide more free resources like this! Consider supporting and getting more amazing pharmacology content! Head on over to meded101.com/nurse
